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Abstract: The Popeye domain containing (POPDC) genes encode a novel class of cAMP effector
proteins, which are abundantly expressed in heart and skeletal muscle. Here, we will review their
role in striated muscle as deduced from work in cell and animal models and the recent analysis of
patients carrying a missense mutation in POPDC1. Evidence suggests that POPDC proteins control
membrane trafficking of interacting proteins. Furthermore, we will discuss the current catalogue of
established protein-protein interactions. In recent years, the number of POPDC-interacting proteins
has been rising and currently includes ion channels (TREK-1), sarcolemma-associated proteins serving
functions in mechanical stability (dystrophin), compartmentalization (caveolin 3), scaffolding (ZO-1),
trafficking (NDRG4, VAMP2/3) and repair (dysferlin) or acting as a guanine nucleotide exchange
factor for Rho-family GTPases (GEFT). Recent evidence suggests that POPDC proteins might also
control the cellular level of the nuclear proto-oncoprotein c-Myc. These data suggest that this family
of cAMP-binding proteins probably serves multiple roles in striated muscle.
Keywords: atrioventricular block; cyclic AMP; cardiac arrhythmia; membrane trafficking; membrane
protein; limb-girdle muscular dystrophy; sinus bradycardia
1. Introduction
The Popeye domain containing genes encode a class of 31-51-cyclic adenosine monophosphate
(cAMP) effector proteins, which is abundantly expressed in cardiac and skeletal muscle [1]. The second
messenger cAMP is an ancient signaling molecule, which is present in all living organisms from
bacteria to humans [2,3]. It is a universal indicator of environmental stress and causes a large number
of different physiological reactions. An intricate network of cAMP-producing enzymes (adenylate
cyclases), effector proteins, cAMP-degrading enzymes (phosphodiesterases), as well as scaffolding
proteins (e.g., AKAPs) are present in eukaryotic cells [4]. This protein network ensures that the
production of cAMP is compartmentalized, allowing the activation of cAMP effector proteins and their
downstream targets in a spatio-temporally-controlled manner [5].
In eukaryotes, three well-characterized classes of cAMP effector proteins are known: protein
kinase A (PKA), exchange factor directly activated by cAMP (EPAC) and the cyclic nucleotide-gated
ion channels (CNGC) [6]. Recently, the cyclic nucleotide receptor involved in sperm function (CRIS)
has been identified as the fourth cAMP effector protein and plays a role in sperm maturation and
motility [7]. The Popeye domain containing (POPDC) genes encode a fifth class of cAMP-effector
proteins, which displays a prominent expression in striated muscle tissue [8]. Work in model organisms
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revealed important roles of POPDC genes for cardiac pacemaking and conduction and for skeletal
muscle regeneration and maintenance of structure and function [9–11]. Recently, the first patients
carrying mutations in POPDC genes were reported, who suffer from muscular dystrophy and cardiac
arrhythmia [12]. In this review article, we will introduce the POPDC gene family, describe their
subcellular localization and discuss their functional roles in skeletal muscle and heart. We will update
the reader on striated muscle proteins that are interacting with POPDC proteins. Finally, we will
discuss some recent evidence suggesting an important role of POPDC proteins in the control of cell
proliferation and wound healing.
2. Structural Elements of the Popeye Domain Containing Proteins
Parallel attempts by two groups to isolate novel genes with a cardiac-restricted expression pattern
led to the discovery of the first member of the POPDC family, which was named POPDC1 and blood
vessel epicardial substance (BVES) [1,13]. Subsequently, two cDNAs were identified in vertebrates
that displayed significant sequence homology to POPDC1 and, therefore, were named POPDC2 and
POPDC3 [1]. However, POPDC genes display limited homology to other genes.
POPDC genes encode membrane proteins, which consist of about 290–370 amino acids and have
predicted molecular weights of 34–42 kDa. In contrast, the native proteins isolated from striated muscle
tissue display significant larger molecular weights (55–70 kDa). Interestingly, the electrophoretic
mobility of POPDC1 differs, when isolated from cardiac or skeletal muscle. In cardiac muscle, the
major immunoreactive POPDC1 protein bands run at a molecular weight of 55–58 kDa, while in
skeletal muscle, POPDC1 has an apparent molecular weight of 70 kDa [8,14]. It is thought that
this may be based on tissue-specific differences in N-glycosylation [1,15], but could also be due to
other types of posttranslational modifications or be the result of tissue-specific alternative splicing.
The extracellularly-localized amino terminus of a POPDC protein is short (20–40 residues) and followed
by three transmembrane domains (Figure 1A). The intracellular part of the protein consists of the
evolutionarily-conserved Popeye domain, which acts as a cAMP-binding domain. Distal to the Popeye
domain is the carboxy terminus region, which is variable in size and differs between family members,
but displays interspecies conservation [1]. The carboxy terminus of POPDC proteins contains clusters
of serine/threonine residues, which get phosphorylated in response to β-adrenergic stimulation [16].
Structural predictions of the Popeye domain suggest it may largely resemble the secondary
structure of the cAMP-binding domain of PKA [10]. However, the two proteins otherwise lack sequence
homology. A three-dimensional model of the Popeye domain was generated on the basis of similarity
to the cAMP-binding domain of the cyclic AMP receptor protein (CRP) from Streptomyces coelicolor,
which displays 20% sequence identity over 149 residues [10]. Using this structural model (Figure 1B),
the majority of the conserved residues were mapped to the phosphate-binding cassette (PBC) or
to immediately surrounding parts of the Popeye domain [10]. The PBC of POPDC proteins do not
resemble the consensus sequence of other cAMP-binding proteins (Figure 1C). Importantly, divergent
PBCs are also present in a number of other proteins, where the small molecule that binds to this
domain is not cAMP, but for example, heme or chlorophenolacetic acid [17].
We therefore need to address whether POPDC proteins do indeed bind cAMP. There is plenty of
evidence in support of a cAMP-binding property of POPDC proteins: (1) The recombinant Popeye
domain of mouse POPDC1 binds cAMP with high affinity, which is in the range of PKA [10]. In the
same assay, the binding affinity for cGMP is approximately 45-fold lower than for cAMP (cAMP
IC50: 118.4 ˘ 7.1 nM; cGMP IC50: 5.27 ˘ 0.68 µM), which suggests that POPDC proteins have a high
specificity for cAMP and therefore being able to discriminate between closely-related cyclic nucleotides.
(2) Assays in Xenopus oocytes and HEK293 cells, which are based on the interaction of POPDC1 and
the ion channel TREK-1 (see below), demonstrate that protein-protein interaction is modulated by
cAMP [10]. (3) Mutagenesis of several evolutionary conserved residues, which are located in the
PBC of POPDC1 (D200, E203 and V217) and POPDC2 (D184), cause a strong reduction in the affinity
for cAMP [10]. (4) There is also the identification of patients that carry a mutation in the PBC of
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POPDC1 (S201F, see below) [12] causing a 50% reduction in cAMP-affinity. This mutation is associated
with striated muscle disease, providing further evidence for the regulation of POPDC proteins by
cAMP. Moreover, this finding also clearly demonstrates the biological significance of cAMP-binding of
POPDC proteins.
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phosphorylation in response to β-adrenergic stimulation [16]. The structure of a protozoan POPDC 
protein has an overall identical structure, suggesting an ancient origin of the POPDC protein family. 
(B) Structural model of the Popeye domain of POPDC1. The 3D model depicted here was generated 
using the First Glance in Jmol website [18]. The structural elements (roof, hinge and lid) of the 
Popeye domain have been identified based on their similar location in other cAMP-binding domains 
[6]. (C) Comparison of the PBC of POPDC proteins and that of canonical cyclic nucleotide 
monophosphate (cNMP)-binding proteins. In POPDC proteins, cAMP-binding involves the  
ultra-conserved sequence motifs DSPE and FQVT. Experimental evidence for the involvement in 
cAMP-binding has been obtained for D200, S201, E203 and V217 (asterisks). The canonical cAMP-binding 
cassette strongly diverges from the one present in POPDC proteins. Sequence data utilized for the 
generation of the logo for the Popeye domain were retrieved from the PFAM entry of the Popeye 
domain [19]. For the protein sequences of non-POPDC cAMP binding proteins, the data were 
downloaded from Prosite (PS00889; CNMP_BINDING_2) [20,21]. (D) A phylogenetic tree of 
vertebrate and invertebrate POPDC protein sequences. The vertebrate Popdc proteins cluster into 
three groups: POPDC1, POPDC2 and POPDC3. The POPDC1 and POPDC3 proteins of the 
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Figure 1. The Popeye domain containing protein family. (A) Graphic depiction of the domain structure
of POPDC p oteins. POPDC proteins consist of a short extracellular amino ter i us, which is subject to
N-glyco ylation, followed by three transmembrane domains and the Popeye omain. Th approximate
location of the invariant DSPE motif, which is part of the phosphate-binding cassette (PBC), is indicated.
The carboxy terminal part of the proteins is variable in size, differs between family members and
contains a cluster of serine/threonine residues, which are subject to phosphorylation in response to
β-adrenergic stimulation [16]. The structure of a protozoan POPDC protein has an overall identical
structure, suggesting an ancient origin of the POPDC protein family. (B) Structural model of the
Popeye domain of POPDC1. The 3D model depicted here was generated using the First Glance in Jmol
website [18]. The structural elements (roof, hinge and lid) of the Popeye domain have been identified
based on their similar location in other cAMP-binding domains [6]. (C) Comparison of the PBC of
POPDC proteins nd that of cano ical cyclic nucleotide monophosphate (cNMP)-binding proteins.
In POPDC proteins, cAMP-binding involves the ultra-conserved sequence motifs DSPE a d FQVT.
Experimental evidence for the i volvement in cAMP-binding has been obtai ed for D200, S201, E203
and V217 (asterisks). The canonical cAMP-binding cassette strongly diverges from the one present in
POPDC proteins. Sequence data utilized for the generation of the logo for the Popeye domain were
retrieved from the PFAM entry of the Popeye domain [19]. For the protein sequences of non-POPDC
cAMP binding proteins, the data were downloaded from Prosite (PS00889; CNMP_BINDING_2) [20,21].
(D) A phylogenetic tree of vertebrate and invertebrate POPDC protein sequences. The vertebrate Popdc
proteins cluster into three groups: POPDC1, POPDC2 and POPDC3. The POPDC1 and POPDC3
proteins of the urochordate Ciona savignyi appear to be orthologous to their respective vertebrate
counterparts, supporting a model of two gene duplication events during chordate and vertebrate
evolution, respectively. Popdc proteins in other invertebrates do show similarity to either Popdc1
or Popdc2/3, and thus, protein ancestry cannot be easily deduced from this analysis. The tree was
generated with the help of the Phylogeny online platform [22].
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We can therefore conclude that cAMP signaling in eukaryotes is mediated by at least two different
groups of effector proteins, those with a canonical PBC (PKA, EPAC, CNGC and CRIS) and POPDC
proteins, which harbour a divergent PBC.
3. Evolution of the Popeye Domain Containing Proteins
While in vertebrates, three POPDC genes are found, only two genes are present in lower chordates
(tunicates, lancelets) and echinoderms. POPDC genes are also present in invertebrates. In molluscs
and insects, most species have two POPDC genes. Interestingly, Drosophila has only a single POPDC
gene [23], whereas the POPDC gene is absent in Caenorhabditis elegans. In vertebrates, POPDC1 and
POPDC3 are tandem-localized, and in humans, both genes are present on chromosome 6q21, while
POPDC2, is located at 3q13.33. A similar genomic organization with two genomic loci is also found in
other vertebrate species.
POPDC proteins have evolved early during animal evolution. Recent GenBank analysis identified
POPDC proteins also in protozoans (NCBI: XP_013760779.1) (Figure 1A). Surprisingly, despite several
billions of years of evolutionary time that separate the vertebrates and protozoans, the overall structure
appears to be very similar, suggesting strong evolutionary pressure to maintain the sequence and the
resulting protein structure. No evidence was obtained so far for the presence of POPDC proteins in
plants or fungi.
A phylogenetic tree has been constructed using the protein sequences of human POPDC1–3 and
of the vertebrate model organism (mouse, chick, Xenopus and zebrafish) (Figure 1D). In addition,
representatives of major clades, basic chordates (Ciona), insects (Drosophila, Apis), chelicerates
(Parasteatoda), molluscs (Aplysia), coelenterates (Hydra) and protozoa (Thecamonas), were aligned,
and sequence divergence representing phylogenetic distance was visualized using a phylogenetic
tree. Vertebrate POPDC family members cluster into three groups representing Popdc1, Popdc2
and Popdc3. Significantly, Popdc1 is well separated from Popdc2 and Popdc3, which are more
similar to each other. The presence of three genes is probably due to two gene duplication events, as
previously proposed [24]. The first gene duplication event generated Popdc1 and Popdc3 and seems
to predate the common ancestor of chordates, as it is shared by all vertebrates, urochordates and
cephalochordates [25]. The second duplication event probably took place during vertebrate evolution
and generated Popdc2, which is unique to vertebrates and localized on a different chromosome than
Popdc1 and Popdc3 [1]. Popdc genes in non-chordate invertebrates appear to have evolved separately
from the chordate genes, and therefore, orthology cannot be determined.
As mentioned above, there is no significant sequence homology between POPDC proteins and
any of the other eukaryotic cAMP effector proteins. However, some of the bacterial cAMP-regulated
transcription factors, catabolite activator protein (CAP) and cAMP receptor protein (CRP), display
weak, but significant sequence homology, which formed the basis for the development of a structural
model of the Popeye domain (Figure 1B) [12].
4. The POPDC Gene Family Encodes Membrane Proteins Predominantly Expressed in Skeletal
Muscle and Heart
Expression of POPDC genes in the mouse embryo has been reported for Popdc1 and
Popdc2 [1,11,26,27]. Expression of Popdc2 was mostly monitored with the help of a LacZ knock-in
(KI) reporter allele [27]. Expression was first detectable between Embryonic Day (E) 6.0 and 7.5 in
the extraembryonic mesoderm and in the heart. At E8.5, Popdc2 was found in the tubular heart,
pericardium and amnion. At E10.5, expression was present in the mesothelial layer of the coelomic
wall, extraembryonic tissues, the heart and muscle precursors in the head and body wall. At E12.5,
expression was present in the coelomic wall, heart and skeletal muscle tissues. At this stage, expression
in the heart was confined to the myocardium and was absent from epi- and endocardium. Smooth
muscle cells of the developing gastrointestinal tract and bladder were also stained. Expression of Popdc1
was studied by enzyme histochemistry in mouse embryos carrying a LacZ KI allele and by whole
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mount in situ hybridisation [11]. With the help of both techniques, expression in the myocardium,
skeletal muscle and smooth muscle of gut and bladder was described. As for Popdc2, expression
of the Popdc1 LacZ allele was confined to the myocardium, and expression was absent in epi- and
endocardium and their derivatives. In contrast, Smith et al. reported POPDC1 protein expression in
coronary artery smooth muscle cells [26]. Differences in detection limits, antibody specificities and
tissue-specific epitope expression may explain the divergent outcomes of these expression studies.
In the adult, POPDC proteins are expressed strongly in cardiac and skeletal muscle. In the heart,
the expression level of POPDC1 is higher in the atria than in ventricles, while POPDC2 is expressed
equally in both chamber types [10,27,28]. High levels of POPDC1 and POPDC2 expression are seen in
the sinoatrial (SAN) and atrioventricular (AVN) nodes [10,27]. Moreover, the ventricular conduction
tissue displays higher levels than the working myocardium (Figure 2). In addition to striated muscle
tissue, POPDC proteins are also strongly expressed in smooth muscle tissue lining the digestive tract,
the uterus and the bladder [10,27,28]. Moreover, sensory neurons in the dorsal root ganglia, as well
as neurons in the central nervous system express POPDC1 and POPDC3. Expression has also been
described in epithelial cells of the digestive tract and the cornea [27,29].
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working myocardium. Frozen sections of mouse myocardial tissue were immunohistochemically 
stained with antibodies directed against POPDC1 (red signal) and, as a marker of ventricular 
conduction tissue, Cx40 (green signal). The white arrows in (D–I) label ventricular conduction tissue, 
while the turquoise arrows label ventricular working myocardium. 
In cardiac myocytes, POPDC1 and POPDC2 are localized to the plasma membrane and are 
present at the intercalated disk, lateral membrane and in the t-tubuli system [10,27,28]. In addition, 
POPDC proteins have also been localized to the nuclear envelope [30,31]. It will be interesting to 
define their function in the nuclear compartment and their possible roles in diseases that are 
2. Dif erential expression of POPDC1 in the murine heart. POPDC1 is expressed at higher levels
in the (A–C) atria, (D–F) His bundle and (G–I) Purkinje fibres in comparis n to the ventricular working
myocardium. Frozen secti ns of mouse myocardial tissue were immunohistochemically stained with
ant bo ies directed against POPDC1 (red signal) and, as a marker of ventricular conductio t ssue,
Cx40 (gree signal). The white arrows in (D–I) label ventricular conduction iss e, while the turquois
arrows label ventricular orking myocardium.
I cardiac myocytes, POPDC1 and PO DC2 are localized to the plasma me brane and are present
at the intercalated disk, lateral membrane and i the t-tubuli system [10,27,28]. In additio , POPDC
proteins have also been localized t the nuclear envelope [30,31]. It will be interesting to define their
function in the uclear compartment and their possible roles in diseases that are associated with
the nuclear envelope, such as dilated cardiomyopathy (DCM), Emery-Dreifuss muscular dystrophy
(EDMD) and limb-girdle muscular dystrophy (LGMD) [28].
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A peculiar observation is the finding that POPDC proteins are also present in the nucleoplasm.
POPDC proteins accumulate in the nucleus, when a cDNA is transfected that encodes a protein
lacking the transmembrane domains. Interestingly, endogenous POPDC1 protein is nuclear-localized
in activated satellite cells, but the protein is cytoplasmic after myoblasts have fused and myotubes
have formed [32]. The functions of nuclear POPDC proteins have not been elucidated yet, but
an involvement in muscle regeneration has been proposed [11,32].
5. Muscle Regeneration Is Retarded in Popdc1 Mouse Mutants
A Popdc1 null mutant allele was engineered by replacing the coding region of the first exon
with a nuclear LacZ reporter gene [11]. The mutant animals were subjected to isoproterenol-induced
cardiac hypertrophy and cardiotoxin-induced skeletal muscle wounding. While the hypertrophic
response in the myocardium was similar between mutant and wildtype, skeletal muscle regeneration
appeared to be retarded in the null mutant mice, as indicated by the prolonged expression of myogenic
transcription factors and the histology of the regenerating muscle. Importantly, Popdc1 expression
is induced in activated satellite cells [11]. At present, however, the precise role of POPDC1 during
muscle regeneration has not been fully understood. Furthermore, a reduction in the ability to cope
with myocardial ischemia-reperfusion injury was reported for Popdc1 null mutant mice [33], suggesting
a broader role of Popdc1 in response to striated muscle injury.
6. Mouse Popdc1 and Popdc2 Mutants Develop a Stress-Induced Sinus Node Bradycardia
A mouse Popdc2 null mutant allele was engineered in a similar way as for Popdc1 by placing
a LacZ reporter gene into the first coding exon [10]. Expression analysis of the LacZ reporter gene of
both mutant alleles, as well as immunohistochemical detection of the endogenous proteins revealed
a prominent expression in the cardiac conduction tissue, including the SAN and AVN (Figure 2) [10].
This observation prompted an investigation of cardiac pacemaking and conduction by implanting
a telemetric ECG devise into null mutants. Cardiac conduction was normal in resting mouse mutants.
However, a stress-induced sinus node bradycardia developed after subjecting null mutants to physical
or emotional stress or after isoproterenol injection [10]. This phenotype was observed not only in
Popdc2, but also in Popdc1 null mutants. Significantly, the pathological phenotype developed in both
mutants in an age-dependent manner. While the pathological phenotype was not present in young
animals, null mutant mice at 5–8 months of age developed a severe stress-induced bradycardia with
episodes of sinus node dysfunction [10].
7. Popdc2 Depletion in Zebrafish Is Associated with Atrioventricular Block and Muscular Dystrophy
Like other vertebrates, three POPDC genes are present in zebrafish. Similar to mammalian and
avian hearts, expression of zebrafish popdc1 and popdc2 is first detectable in the heart just shortly
before cardiac contraction starts [9,12]. Expression of popdc1 and popdc2 in embryonic skeletal muscle
is observed once myotubes are beginning to differentiate in the myotome. Expression of popdc2 in
tail musculature is transient and is absent by 3 dpf; however, it remains present in the heart and
in facial muscles [9]. In the adult, expression of both popdc1 and popdc2 is detected in heart and
skeletal muscle [9,12]. Depletion of popdc2 with morpholino oligonucleotides targeted to the splice
acceptor and donor sites caused a strong loss-of-function phenotype. In the heart, a massive pericardial
effusion developed, which is a sign for embryonic heart failure. When the morpholino concentration
was reduced, the pericardial effusion became smaller, while a second cardiac phenotype emerged,
i.e., an atrioventricular (AV)-block. Initially, morphant hearts were beating regularly until 4–5 days
post fertilization (dpf), when a 2:1 or 3:1 AV-block phenotype was observed [9]. As the morphants
grew older, hearts were observed with extensive sinus pauses or with an electrically silent ventricle.
In skeletal muscle, a severe muscular dystrophy phenotype was present [9]. It is thought that the
malformation of the myotendinous junctions (MTJ), which probably does not allow proper anchoring
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of the myofibrils into the MTJ, contributes to the dystrophy phenotype. In addition to the aberrant tail
musculature in the popdc2-depleted embryos, a dysmorphic facial musculature is observed. A similar
striated muscle pathology including AV-block and muscular dystrophy was also observed in the case
of popdc1 morphants [12].
8. A POPDC1S201F Mutation Causes Limb-Girdle Muscular Dystrophy and Cardiac Arrhythmia
As discussed in the previous sections, null mutations and depletion of Popdc1 and Popdc2 in animal
models caused severe pathologies in the heart and skeletal muscle. However, until recently, it was
uncertain whether POPDC gene mutations were disease-associated in humans and whether patients
carrying mutations develop pathologies similar to those observed in model organisms. Recently,
a family carrying a recessive missense (S201F) mutation in POPDC1 and suffering from limb-girdle
muscular dystrophy (LGMD) was identified (Figure 3A). The patients display an early onset AV-block
coupled with a late onset mild muscular dystrophy (Figure 3B) [12]. This novel LGMD was recently
classified as LGMD2X [34].
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(F,G) TEM analysis of trunk skeletal muscle of (F) WT and (G) homozygous popdc1S191F/S191F F mutant 
Figure 3. The POPDC1S201F missense t ti causes cardiac arrhythmia and muscular dystrophy.
(A) Pedigree of an Italian family homozygous for the POPDC1S201F mutation. The index patient (III-2,
arrow) and his brother (III-1) suffer from AV block, while the grandfather (I-1) has both, AV block
and LGMD. (B) Holter electrocardiogram of the index patient displaying an episode of a paroxysmal
AV block. (C) 3D model of the Popeye domain. Only the phosphate-binding cassette (PBC) is shown.
Two hydrogen bonds are formed by S201, but these are predicted to be lost when the S201 residue is
replaced by a phenylalanine (turquoise) affecting the ligand-binding affinity of the Popeye domain.
(D–G) Sections through the zebrafish tail musculature. (D,E) Confocal analysis of actin (phalloidin
staining, red channel) and dystrophin (green channel) in trunk skeletal muscle of (D) WT (popdc1+/+)
and (E) homozygous zebrafish mutant (popdc1S191F/S191F) at 5 dpf. Ho ozygous mutants develop
lesions in skeletal muscle. Muscl fibre detach from the MTJ and retract. Arrowh ads indicate
the presence of dystrophin immunoreactivity at the end of the ruptured fibres, suggesting that the
fibres have lost connection to the MTJ, but probably remain physically intact. (F,G) TEM analysis of
trunk skeletal muscle of (F) WT and (G) homozygous popdc1S191F/S191F F mutant zebrafish embryos at
5 dpf. The MTJ in the mutant is characterized by a lack of electron-dense material. Panels (A–G) are
reproduced from [12] with permission.
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LGMD is a heterogeneous group of muscular dystrophies, which primarily affect hip and
shoulder muscles [35]. There are both autosomal dominant (LGMD1) and autosomal recessive
(LGMD2) subtypes known. To date, 31 different genetic loci of LGMD have been identified, most
of them inherited in an autosomal recessive fashion. LGMD-causing genes encode proteins that
belong to several different cellular pathways, including sarcolemmal glycoproteins (dystroglycan
and sarcoglycans), scaffolding proteins (caveolin-3 (CAV3)), membrane repair and vesicle trafficking
proteins (dysferlin (DYSF)) and nuclear envelope proteins (lamin A/C (LMNA)) [35].
A significant number of the LGMD gene mutations not only cause a muscular dystrophy, but also
cardiac phenotypes, including a progressive reduction in ventricular ejection fraction, heart failure
and cardiac arrhythmia [36]. Interestingly, in many cases, the pathology in the heart is early onset and
more severe than in skeletal muscle [37].
The mutated residue S201 in POPDC1 is ultra-conserved and part of the DSPE motif of the PBC
(Figures 1C and 3C). S201 is thought to be directly involved in nucleotide binding. Indeed, measuring
cAMP-binding of the mutant protein revealed a significant reduction [12]. In order to generate
an animal model for this human missense mutation, a homologous mutation was introduced into
the orthologue in zebrafish. The resulting homozygous popdc1S191F/S191F mutant fish also displayed
muscular dystrophy (Figure 3D–G) and cardiac arrhythmia and, therefore, largely resembled the
mutant phenotype observed in patients [12]. The human S201F mutation is rare, and screening of
an additional 104 patients with cardiac arrhythmia and/or muscular dystrophy did not reveal any
additional carrier [12].
Recently, POPDC1 was identified as a hub gene for atrial fibrillation (AF) using a weighted
co-expression network analysis [38]. However, no POPDC1 mutations have yet been identified in
AF patients. POPDC1 has been recently identified as a novel genetic determinant of the QT interval
and QRS duration [39]. Expression of POPDC genes is downregulated in heart failure (HF) [40].
The reduction in POPDC gene expression and the resulting loss of POPDC protein expression in
the failing hearts may contribute to the myocardial arrhythmia, which is prevalent in heart failure.
However, more work in animal models is required to define whether the reduction in POPDC
expression is causally related to the disease phenotype in heart failure.
A number of different functions and associated pathologies in striated muscle tissue have been
associated with POPDC genes both in animal models and in patients (Table 1). However, there seems
to be also species-specific differences. Both, in zebrafish morphants and mutants, an AV-block has
been described. Similarly, patients with a S201F missense mutation of POPDC1 display an AV-block.
In contrast, Popdc1 and Popdc2 null mutants have a stress-induced sinus bradycardia, while an AV-block
has not yet been described. These phenotypic differences in model organisms and patients may be
related to the vastly different heart rates in mice compared to zebrafish and humans [41].
Table 1. Cardiac and skeletal muscle functions of Popdc proteins.
Function Reference
POPDC genes are predominantly expressed in striated muscle [1]
Popdc1´/´ mice display a reduction in the number and an increase in the size of caveolae [33]
Popdc1´/´ mice display an increased vulnerability to ischemia-reperfusion injury [33]
Popdc1 controls membrane trafficking of TREK-1 [10]
Popdc1 or Popdc2 null mutant mice display an age-dependent stress-induced bradycardia phenotype [10]
Depletion of either Popdc1 or Popdc2 in mice results in structural remodelling of SAN tissue [10]
Depletion of popdc1 or popdc2 in zebrafish causes AV-block and muscular dystrophy [9,12]
Popdc1 in zebrafish controls the formation of the myotendinous junction [12]
The missense mutation POPDC1S191F causes cardiac arrhythmia and muscular dystrophy in patients [12]
POPDC1 and POPDC3 are downregulated in human heart failure [40]
POPDC1 has been associated with atrial fibrillation [38]
POPDC1 is a novel genetic determinant of the QT interval and the QRS time [39]
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9. Interaction Partners of POPDC Proteins
9.1. Zonula Occludens-1
The first interaction partner of POPDC proteins that was identified is the PDZ protein Zonula
occludens-1 (ZO1) [42]. ZO-1 functions as a scaffolding protein of tight junctions and contains several
protein domains, with which it interacts with other proteins, such as the tight junction proteins claudin
and occludin, actin and several signaling proteins [43]. The downregulation of POPDC1 in cultured
epithelial cells reduces transepithelial resistance and junctional protein localization at the plasma
membrane, which suggests that POPDC1 contributes to the establishment and/or maintenance of
epithelial integrity [42]. In cardiac myocytes, ZO1 binds the carboxy terminus of the gap junction
protein Connexin43 (Cx43) and thereby controls gap junction plaque size [44]. Thus, the POPDC1/ZO-1
interaction could be of significance with respect to cardiac conduction. While POPDC proteins
are expressed throughout the sarcolemma, some antibodies directed against POPDC1 or POPDC2,
specifically, recognize an expression domain in the intercalated disk region [26,45,46]. Interestingly,
cAMP signaling via PKA and EPAC modulates membrane trafficking of Cx43 and stimulates gap
junction neo-formation in neonatal cardiac myocytes [47]. Modulation of PKA and EPAC has also been
implicated in myocardial protection and prevention of post-ischemic cardiac arrhythmia, which is also
observed in Popdc1 null mutant mice [33,48].
9.2. VAMP2/3, GEFT and NDRG4
With the help of a yeast-two-hybrid assay, three interacting proteins, namely vesicle-associated
membrane protein 3 (VAMP3) [49], N-myc downstream regulated gene 4 (NRDG4) [50] and guanine
nucleotide exchange factor T (GEFT) [51], were identified. VAMP3 and the closely-related protein
VAMP2 are SNARE proteins, which act as components of the vesicle docking and fusion complex [52].
VAMP proteins are involved in membrane trafficking of a number of different receptor proteins
through the recycling endosome. Thus, VAMP2 and VAMP3 have both been implicated in GLUT4
translocation in cardiac and skeletal muscle [53,54]. Interestingly, VAMP2 has been found to be
expressed in satellite cells and is upregulated after cardiotoxin injection [55]. Thus, the protein-protein
interaction of POPDC1 with VAMP2 and VAMP3 could be of relevance in the context of the observed
regeneration defect in the Popdc1 null mutant [11].
Moreover, VAMP2/VAMP3 also play an important role in the control of cell adhesion and cell
migration, mainly through the modulation of integrin receptor recycling [56,57]. This function of
VAMP proteins could also be of relevance in striated muscle regeneration. Moreover, integrin receptor
recycling may also be required for the maintenance of the MTJ in zebrafish embryos, which is strongly
affected in popdc1 mutants and popdc2 morphants [9,12]. The stability of the MTJ depends on two
membrane receptor complexes, i.e., the dystrophin glycoprotein complex (DGC) and the integrin
receptor [58,59]. Both receptor complexes bind the basement membrane protein laminin 2 and, thereby,
anchor the muscle cell to the MTJ [60]. Loss-of-function mutations in each of these proteins cause
a phenocopy of the MTJ phenotype in POPDC1 mutants. Thus, it will be important to work out the
epistatic relationship of the different proteins acting in this context. Interestingly, the role of cAMP
in MTJ formation is currently unknown. It is noteworthy that cAMP levels in astrocytes modulate
membrane trafficking of VAMP3. Therefore, POPDC proteins could be involved in recruiting VAMP3
to the plasma membrane [61]. A role for POPDC1 in membrane trafficking is also supported by the
fact that Popdc1 interacts with NDRG4 [50]. Knockdown of both Popdc1 and Ndrg4 affects VAMP3
vesicle docking. In addition, loss of Ndrg4 also affects cell migration via fibronectin/integrin receptor
internalization [50].
GEFT, a guanine nucleotide exchange factor (GEF) for the Rho-family GTPases Rac1 and Cdc42,
has also been identified as an interaction partner of POPDC1 [51]. GEFT is expressed in cardiac
and skeletal muscle. Overexpression of GEFT causes a rearrangement of the microfilaments and
affects the morphology and migratory activity of cells. Forced expression of a construct, encoding
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a POPDC1 mutant protein lacking the transmembrane domains, affected the activation of Rac1 and
Cdc42 without affecting RhoA [51]. Furthermore, transfection of the same construct into C2C12 cells
attenuated muscle differentiation. How POPDC1 modulates GEFT is currently unknown, and several
mechanisms have been proposed, including direct control of GEFT activity, sequestration of GEFT and,
therefore, preventing it from activating downstream effectors or recruiting it to a particular subcellular
localization [51,62]. GEFT has also been implicated in skeletal muscle regeneration [63]. Moreover, it
also needs to be mentioned that GEFT controls neurite outgrowth [64]. Interestingly, in Popdc1 and
Popdc2 null mutants, SAN myocytes display structural abnormalities, which might be due to aberrant
GEFT activity [10].
9.3. TREK-1
The presence of POPDC proteins in the plasma membrane of cardiac myocytes and the high
expression levels in the cardiac conduction system prompted a search for ion channels that interact
with POPDC proteins. This led to the identification of the potassium channel TWIK-related K+
channel 1 (TREK-1) as a novel POPDC interacting protein [10]. TREK-1 is a member of the two-pore
domain potassium channel (K2P) family, which is modulated by membrane stretch, intracellular pH,
temperature, phosphorylation and protein–protein interactions [65]. Co-expression of any one of the
three POPDC proteins and TREK-1 in Xenopus oocytes resulted in an approximately two-fold higher
current, when compared to oocytes in which TREK-1 was expressed alone [10]. The increase in TREK-1
current can be explained by an enhanced membrane trafficking of the ion channel in the presence of
POPDC proteins [10]. This effect was modulated by cAMP-binding to POPDC proteins and was lost in
the presence of increased cAMP levels.
It is thought that the carboxy terminus of POPDC1 is directly interacting with TREK-1, as
demonstrated by a GST pull-down experiment using carboxy-terminal POPDC1 as bait [10]. Moreover,
a bi-molecular FRET sensor consisting of POPDC1-CFP and YFP-TREK-1 demonstrated direct physical
interaction [10]. Moreover, the FRET ratio obtained under baseline conditions decreased after raising
the intracellular cAMP levels, suggesting that cyclic nucleotide-binding induces an allosteric effect in
the Popeye domain, which affects the interaction with TREK-1.
Interestingly, TREK-1 in myocytes interacts with βIV-spectrin and ankyrin G [66], which are
involved in membrane targeting and complex formation of a number of cardiac ion channels [67].
A cardiac-specific knockout of Kcnk2 encoding TREK-1 displays a stress-induced sinus bradycardia
similar to the one observed in Popdc1 and Popdc2 null mutants [68], which means that the sinus
bradycardia phenotype of POPDC mutants could at least be partially explained by the loss of the
POPDC-TREK-1 interaction.
In support of a role of POPDC proteins in regulating membrane trafficking is the recent finding that
the mutant POPDC1S201F protein in the muscle tissue of the LGMD2X patients displayed a reduction
in membrane localization and increased perinuclear levels. POPDC2 was localized in a similar way
in the mutant muscle. Surprisingly, the increase of cAMP levels caused a reduction in membrane
localization of TREK-1 in the presence of POPDC1S201F, whereas a reduction in the cAMP-binding
affinity of POPDC1S201F caused a reduction in the membrane transport of itself and of POPDC2. These
data suggest that the effect of cAMP on membrane trafficking of POPDC1 and associated proteins is
complex. Therefore, more work is required to unravel how cAMP-binding of POPDC proteins affects
protein-protein interaction and membrane trafficking.
9.4. Caveolin-3, Dystrophin and Dysferlin
The sarcolemmas of skeletal and cardiac muscle are complex structures and contain caveolae,
which cover the entire cell surface, and t-tubules, which are plasma membrane invaginations into
the centre of muscle cells. Both structures contribute to membrane compartmentalization. Different
ion channels accumulate specifically in caveolae and t-tubules [69]. Interestingly, caveolae have been
implicated in mechanosensing and mechanoprotection [70]. Both caveolae and t-tubules have been
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linked to caveolin-3 (CAV3), the major membrane protein of caveolae in striated muscle [71]. Cav3 null
mutant mice display muscular dystrophy and cardiomyopathy. They lack caveolae and display an
abnormal t-tubular structure in skeletal muscle, whereas a reduction in caveolar number was observed
in cardiac muscle [72,73].
Recently, an interaction of POPDC1 and CAV3 has been reported [33]. The binding site for CAV3
has been mapped to a motif located in the lid structure of the Popeye domain (Figure 1B). Popdc1
null mutants display a reduction in the number and an increase in the diameter of caveolae [33].
Interestingly, amongst other muscle and heart conditions, mutations of CAV3 have been linked to
an autosomal dominant form of LGMD (LGMD1C) [34]. In Popdc1 null mutants, altered Ca2+ transients
were observed [33]. Thus, the loss of POPDC proteins may result in abnormal caveolar and t-tubular
organisation and functions, which may affect physiological parameters, such as ion currents. Changes
in compartmentalization may be responsible for the abnormal stress-induced arrhythmia observed in
Popdc1 and Popdc2 null mutants [10]. However, in muscle biopsies of LGMD2X patients carrying the
POPDC1S201F mutation, membrane localization of CAV3 was not affected [12]. While the demonstration
of a physical interaction between POPDC1 and CAV3 and overlapping pathological phenotypes in
patients and in model organisms is compelling, the biological significance of this protein-protein
interaction is currently uncertain and requires more research.
Muscle has the ability to repair an injury by two principle mechanisms: (1) large and significant
injuries that causes fibre degeneration and necrosis are repaired by satellite cell-mediated regeneration;
(2) micro-injuries, on the other hand, are repaired via a mechanism that involves the protein dysferlin,
which recruits other proteins, such as annexins, to the site of membrane damage, leading to a rapid
sealing of the sarcolemma [74]. Skeletal muscle fibres of one of the patients carrying the homozygous
POPDC1S201F mutation display focal loss of the sarcolemma [12]. This phenotype has been previously
observed in patients carrying mutations in anoctamin 5 (ANO5) [75], CAV3 [76] and in Dysf null mutant
mice [77]. Mutations in DYSF have been associated with LGMD type 2B and Miyoshi myopathy [78].
DYSF-mediated membrane repair is also required in cardiac muscle, with its deficiency leading to
cardiomyopathy [79].
POPDC1 and dysferlin are interacting proteins. They are co-localized and co-immunoprecipitated
after co-transfection [12]. However, in muscle biopsies of LGMD2X patients carrying the POPDC1S201F
mutation, membrane localization of dysferlin was not affected [12]. Thus, despite the physical
interaction and presence of membrane discontinuities in muscle tissue of LGMD2X patients, the
biological significance of this protein-protein interaction is currently not fully understood.
Dystrophin (DYS) is a major cytoskeletal protein localized at the subsarcolemmal sarcolemma in
cardiac and skeletal muscle. It forms a link between the cytoskeleton and the sarcolemmal dystrophin
glycoprotein complex (DGC). The DGC consists of α and β-dystroglycan, sarcoglycans, sarcospan,
dystrobrevin, syntrophins and neuronal nitric oxide synthase (nNOS) [80]. Dystrophin mutations
are associated with Duchenne (DMD) and Becker-type muscular dystrophy (BMD). The disease
phenotype in the case of BMD is usually milder and more slowly progressing. DMD is characterized
by progressive loss of functional striated muscle tissue, causing muscular dystrophy and dilated
cardiomyopathy with rhythm defects [81]. Most patients die before they reach the age of 25 [82].
Dystrophin is an interaction partner of POPDC1. Both proteins are co-localized and
co-immunoprecipitated after co-transfection [12]. However, in muscle biopsies of LGMD2X patients,
which carry the POPDC1S201F mutation, membrane localization of dystrophin was not altered [12].
Therefore, at present, the biological role of this interaction is unknown.
9.5. c-Myc
A yeast two-hybrid (Y2H) assay using a human placenta library identified PR61α as a novel
POPDC1-interacting protein [83]. PR61α is a regulatory subunit of protein phosphatase 2A (PP2A),
which is critical for c-Myc degradation [83]. POPDC1 forms a complex with PR61α and c-Myc.
RNAi-mediated knockdown of Popdc1 in cell lines caused an increase in c-Myc levels, whereas forced
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expression caused a decrease. This suggests that POPDC1 controls c-Myc levels in cells by promoting
degradation through complex formation with c-Myc, PR61α and the PP2A catalytic subunit [83].
Interestingly, the PR61α interaction domain was mapped to the carboxy terminus of POPDC1, which
is not conserved between POPDC family members, suggesting that this interaction is probably unique
to POPDC1. Presently, we do not know whether complex formation of POPDC1 with c-Myc, PR61α
and the PP2A catalytic subunit is also observed in striated muscle tissue. If this would be the case,
the POPDC1-mediated modulation of c-Myc levels could have an important impact on myoblast
proliferation and differentiation and, therefore, on muscle regeneration. C-Myc can block myogenic
differentiation even in the presence of the forced expression of myogenic transcription factors, such
as MyoD and myogenin [84]. Similarly, c-Myc has been implicated in perinatal cell proliferation of
cardiac muscle [85,86]. It also plays a role in cardiac hypertrophy and heart failure induction [87,88].
It will be important to test whether deregulated c-Myc expression is also present in striated muscle
tissue of Popdc1 null mutant mice. Such data would be relevant to define the molecular basis for the
regeneration phenotype in Popdc1 null mutants [11].
In summary, in recent years, a number of different proteins have been shown to interact with
POPDC proteins, most of which are localised to the plasma membrane as transmembrane proteins or
as membrane-associated proteins. However, with c-Myc, a nuclear interaction partner has now been
identified, which suggests that POPDC proteins act probably in different subcellular compartments
(Table 2).
Table 2. Popdc interaction partners.
Protein Evidence Reference
TREK-1 GST-PD, Co-IP, Co-IF, FRET, TEVC [10]
Caveolin-3 Co-IP, Co-IF [33]
Dystrophin Co-IP, Co-IF [12]
Dysferlin Co-IP, Co-IF [12]
VAMP2, VAMP3 Y2H, GST-PD, Co-IF [49]
GEFT Y2H, GST-PD, Co-IF [51]
NDRG4 Y2H, GST-PD, Co-IP, Co-IF [50]
ZO1 GST-PD, Co-IF, IG-EM [42]
PR61α Y2H, Co-IP [83]
c-MYC Co-IP, PLA [83]
Abbreviations: Co-IF, co-localisation by immunofluorescence; Co-IPT, co-immunoprecipitation, FRET,
fluorescence resonance energy transfer; GST-PD, glutathione S-transferase pull down; IG-EM, immunogold
electron microscopy; PLA, proximity-ligation-assay; TEVC, two-electrode voltage clamp; Y2H, yeast two hybrid.
10. Outlook
Since the discovery of POPDC proteins in 1999/2000, significant progress in our understanding
of their role has been made [1,13]. Until very recently, it was uncertain whether the cardiac arrhythmia
and muscular dystrophy phenotypes, which are present in animal models, occur in patients. However,
the identification of LGMD patients with a strong cardiac phenotype and who carry a point mutation
in POPDC1 clearly demonstrates the significance of POPDC mutations in muscle disease. They also
show the significance of cAMP-binding of POPDC proteins for normal muscle function. However, the
disease spectrum caused by mutations in POPDC genes needs to be better defined. Since mutations
in POPDC genes are obviously rare, it will also be necessary to define the role of POPDC genes in
acquired heart muscle disease, such as heart failure, atrial fibrillation and ischemia-reperfusion.
Surprisingly, in cardiac and skeletal muscle cells, POPDC proteins are not only present at the
sarcolemma (Figure 4), but also in caveolae, t-tubules, intercalated disk, nuclear envelope and the
nucleoplasm. It is likely that in each subcellular compartment, a specific set of proteins are forming
complexes with POPDC proteins, and defining these complexes will be an important task in the coming
years, resulting in a better understanding of the role of POPDC proteins in health and disease.
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POPDC proteins are a novel class of cAMP-binding proteins, and therefore, the relationship of
POPDC proteins to other cAMP effector proteins needs to be defined. In the case of EPAC and PKA,
both proteins are often co-localized through the interaction with a common AKAP protein [89,90].
It will therefore be interesting to find out whether POPDC protein are also associated with AKAPs
and, thereby, co-localized with EPAC and PKA. Moreover, the biological activity of POPDC proteins in
relationship to EPAC and PKA needs to be established. Currently, the role that POPDC proteins play
in the nuclear envelope and nucleoplasm is poorly characterized. However, it is interesting that PKA
and EPAC1 also have been localized to these compartments [91–93].
Thus, future research will need to take into account the complex expression and subcellular
localization patterns of POPDC proteins and other cAMP effector proteins. This will provide us with
a deeper understanding of the function of POPDC proteins and the physiological effects of cAMP on
cellular systems in general.
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bbreviations
The following abbreviations are used in this manuscript:
AKAP A-kinase anchoring protein
ANO5 anoctamin 5
AV-block atrioventricular block
AVN atrioventricular node
BVES blood vessel epicardial substance
cAMP cyclic adenosine monophosphate
CAP catabolite activator protein
C V3 caveolin 3
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Cdc42 cell division control protein 42 homolog
CFP cyan fluorescent protein
cGMP cyclic guanosine monophosphate
cNGC cyclic nucleotide-gated channel
cNMP cyclic nucleotide monophosphate
CRIS cyclic nucleotide receptor involved in sperm function
CRP cAMP receptor protein
Cx40/43 connexin 40/43
DCM dilated cardiomyopathy
DGC dystrophin glycoprotein complex
DMD Duchenne muscular dystrophy
dpf days post-fertilization
DYS dystrophin
DYSF dysferlin
ECG electrocardiography
EDMD Emery-Dreifuss muscular dystrophy
EPAC exchange protein directly activated by cAMP
FRET Förster resonance energy transfer
GLUT4 glucose transporter type 4
GST glutathione-S-transferase
HF heart failure
IC50 half maximal inhibitor concentration
kDa kilo Dalton
K2P two-pore domain potassium channel
LacZ ß-galactosidase gene
LGMD limb-girdle muscular dystrophy
MTJ myotendinous junction
MyoD myogenic differentiation gene
NCBI national centre for biotechnology information
NDRG4 N-myc downregulated gene 4
PBC phosphate binding cassette
PFAM protein families
PLA proximity ligation assay
POPDC Popeye domain containing
PKA protein kinase A
PP2A protein phosphatase 2
Rac1 Ras-related C3 botulinum toxin substrate 1
RhoA Ras homolog family member A
SAN sinoatrial node
SNARE soluble N-ethylmaleimide-sensitive- factorattachment receptor
TREK-1 TWIK related K+ channel 1
VAMP2/3 vesicle associated membrane protein 2/3
Y2H yeast-two-hybrid
YFP yellow fluorescent protein
ZO1 zona occludens protein 1
References
1. Andrée, B.; Hillemann, T.; Kessler-Icekson, G.; Schmitt-John, T.; Jockusch, H.; Arnold, H.H.; Brand, T.
Isolation and characterization of the novel popeye gene family expressed in skeletal muscle and heart.
Dev. Biol. 2000, 223, 371–382. [CrossRef] [PubMed]
2. Lee, L.C.; Maurice, D.H.; Baillie, G.S. Targeting protein-protein interactions within the cyclic amp signaling
system as a therapeutic strategy for cardiovascular disease. Future Med. Chem. 2013, 5, 451–464. [CrossRef]
[PubMed]
3. Boularan, C.; Gales, C. Cardiac camp: Production, hydrolysis, modulation and detection. Front. Pharmacol.
2015, 6, 203. [CrossRef] [PubMed]
4. Lefkimmiatis, K.; Zaccolo, M. Camp signaling in subcellular compartments. Pharmacol. Ther. 2014, 143,
295–304. [CrossRef] [PubMed]
5. McCormick, K.; Baillie, G.S. Compartmentalisation of second messenger signalling pathways. Curr. Opin.
Genet. Dev. 2014, 27, 20–25. [CrossRef] [PubMed]
J. Cardiovasc. Dev. Dis. 2016, 3, 22 15 of 19
6. Rehmann, H.; Wittinghofer, A.; Bos, J.L. Capturing cyclic nucleotides in action: Snapshots from
crystallographic studies. Nat. Rev. Mol. Cell Biol. 2007, 8, 63–73. [CrossRef] [PubMed]
7. Krahling, A.M.; Alvarez, L.; Debowski, K.; Van, Q.; Gunkel, M.; Irsen, S.; Al-Amoudi, A.; Strunker, T.;
Kremmer, E.; Krause, E.; et al. Cris-a novel camp-binding protein controlling spermiogenesis and the
development of flagellar bending. PLoS Genet. 2013, 9, e1003960. [CrossRef] [PubMed]
8. Schindler, R.F.; Brand, T. The popeye domain containing protein family—A novel class of camp effectors
with important functions in multiple tissues. Prog. Biophys. Mol. Biol. 2016, 120, 28–36. [CrossRef] [PubMed]
9. Kirchmaier, B.C.; Poon, K.L.; Schwerte, T.; Huisken, J.; Winkler, C.; Jungblut, B.; Stainier, D.Y.; Brand, T.
The popeye domain containing 2 (popdc2) gene in zebrafish is required for heart and skeletal muscle
development. Dev. Biol. 2012, 363, 438–450. [CrossRef] [PubMed]
10. Froese, A.; Breher, S.S.; Waldeyer, C.; Schindler, R.F.; Nikolaev, V.O.; Rinne, S.; Wischmeyer, E.; Schlueter, J.;
Becher, J.; Simrick, S.; et al. Popeye domain containing proteins are essential for stress-mediated modulation
of cardiac pacemaking in mice. J. Clin. Investig. 2012, 122, 1119–1130. [CrossRef] [PubMed]
11. Andrée, B.; Fleige, A.; Arnold, H.H.; Brand, T. Mouse pop1 is required for muscle regeneration in adult
skeletal muscle. Mol. Cell. Biol. 2002, 22, 1504–1512. [CrossRef] [PubMed]
12. Schindler, R.F.; Scotton, C.; Zhang, J.; Passarelli, C.; Ortiz-Bonnin, B.; Simrick, S.; Schwerte, T.; Poon, K.L.;
Fang, M.; Rinne, S.; et al. Popdc1s201f causes muscular dystrophy and arrhythmia by affecting protein
trafficking. J. Clin. Investig. 2016, 126, 239–253. [CrossRef] [PubMed]
13. Reese, D.E.; Zavaljevski, M.; Streiff, N.L.; Bader, D. Bves: A novel gene expressed during coronary blood
vessel development. Dev. Biol. 1999, 209, 159–171. [CrossRef] [PubMed]
14. Vasavada, T.K.; DiAngelo, J.R.; Duncan, M.K. Developmental expression of pop1/bves. J. Histochem. Cytochem.
2004, 52, 371–377. [CrossRef] [PubMed]
15. Knight, R.F.; Bader, D.M.; Backstrom, J.R. Membrane topology of bves/pop1a, a cell adhesion molecule that
displays dynamic changes in cellular distribution during development. J. Biol. Chem. 2003, 278, 32872–32879.
[CrossRef] [PubMed]
16. Lundby, A.; Andersen, M.N.; Steffensen, A.B.; Horn, H.; Kelstrup, C.D.; Francavilla, C.; Jensen, L.J.;
Schmitt, N.; Thomsen, M.B.; Olsen, J.V. In vivo phosphoproteomics analysis reveals the cardiac targets
of beta-adrenergic receptor signaling. Sci. Signal 2013, 6, rs11. [CrossRef] [PubMed]
17. Kannan, N.; Wu, J.; Anand, G.S.; Yooseph, S.; Neuwald, A.F.; Venter, J.C.; Taylor, S.S. Evolution of allostery
in the cyclic nucleotide binding module. Genome Biol. 2007, 8, R264. [CrossRef] [PubMed]
18. First glance in jmol. Available online: http://bioinformatics.org/firstglance/fgij/ (accessed on
18 February 2016).
19. Pfam 29.0. Available online: http://pfam.xfam.org (accessed on 23 February 2016).
20. Prosite database of protein domains, proteins, and functional sites. Available online: http://prosite.expasy.org
(accessed on 23 February 2016).
21. Crooks, G.E.; Hon, G.; Chandonia, J.M.; Brenner, S.E. Weblogo: A sequence logo generator. Genome Res.
2004, 14, 1188–1190. [CrossRef] [PubMed]
22. Dereeper, A.; Guignon, V.; Blanc, G.; Audic, S.; Buffet, S.; Chevenet, F.; Dufayard, J.F.; Guindon, S.; Lefort, V.;
Lescot, M.; et al. Phylogeny.fr: Robust phylogenetic analysis for the non-specialist. Nucleic Acids Res. 2008, 36,
W465–W469. [CrossRef] [PubMed]
23. Lin, S.; Zhao, D.; Bownes, M. Blood vessel/epicardial substance (bves) expression, essential for embryonic
development, is down regulated by grk/efgr signalling. Int. J. Dev. Biol. 2007, 51, 37–44. [CrossRef]
[PubMed]
24. Brand, T. The popeye domain-containing gene family. Cell Biochem. Biophys. 2005, 43, 95–104. [CrossRef]
25. Tree of the month: Zebrafish popeye-domain-containing proteins and heartbeat regulation. Available online:
http://phylomedb.org/?q=node/659 (accessed on 31 March 2016).
26. Smith, T.K.; Bader, D.M. Characterization of bves expression during mouse development using newly
generated immunoreagents. Dev. Dyn. 2006, 235, 1701–1708. [CrossRef] [PubMed]
27. Froese, A.; Brand, T. Expression pattern of popdc2 during mouse embryogenesis and in the adult. Dev. Dyn.
2008, 237, 780–787. [CrossRef] [PubMed]
28. Torlopp, A.; Breher, S.S.; Schluter, J.; Brand, T. Comparative analysis of mrna and protein expression of
popdc1 (bves) during early development in the chick embryo. Dev. Dyn. 2006, 235, 691–700. [CrossRef]
[PubMed]
J. Cardiovasc. Dev. Dis. 2016, 3, 22 16 of 19
29. Ripley, A.N.; Chang, M.S.; Bader, D.M. Bves is expressed in the epithelial components of the retina, lens, and
cornea. Investig. Ophthalmol. Vis. Sci. 2004, 45, 2475–2483. [CrossRef] [PubMed]
30. Wilkie, G.S.; Korfali, N.; Swanson, S.K.; Malik, P.; Srsen, V.; Batrakou, D.G.; de las Heras, J.; Zuleger, N.;
Kerr, A.R.; Florens, L.; et al. Several novel nuclear envelope transmembrane proteins identified in skeletal
muscle have cytoskeletal associations. Mol. Cell. Proteom. 2011, 10, M110.003129. [CrossRef] [PubMed]
31. Korfali, N.; Wilkie, G.S.; Swanson, S.K.; Srsen, V.; de Las Heras, J.; Batrakou, D.G.; Malik, P.; Zuleger, N.;
Kerr, A.R.; Florens, L.; et al. The nuclear envelope proteome differs notably between tissues. Nucleus 2012, 3,
552–564. [CrossRef] [PubMed]
32. Schindler, R.; Simrick, S.; Brand, T. Nuclear localization of members of popeye domain containing (popdc)
protein family. Cardiovasc. Res. 2012, 93, S98.
33. Alcalay, Y.; Hochhauser, E.; Kliminski, V.; Dick, J.; Zahalka, M.A.; Parnes, D.; Schlesinger, H.; Abassi, Z.;
Shainberg, A.; Schindler, R.F.; et al. Popeye domain containing 1 (popdc1/bves) is a caveolae-associated
protein involved in ischemia tolerance. PLoS ONE 2013, 8, e71100. [CrossRef] [PubMed]
34. #616812 muscular dystrophy, limb-girdle, type 2x; lgmd2x. Available online: http://www.omim.org
(accessed on 20 October 2014).
35. Thompson, R.; Straub, V. Limb-girdle muscular dystrophies—International collaborations for translational
research. Nat. Rev. Neurol. 2016, 12, 294–309. [CrossRef] [PubMed]
36. Petri, H.; Sveen, M.L.; Thune, J.J.; Vissing, C.; Dahlqvist, J.R.; Witting, N.; Bundgaard, H.; Kober, L.; Vissing, J.
Progression of cardiac involvement in patients with limb-girdle type 2 and becker muscular dystrophies:
A 9-year follow-up study. Int. J. Cardiol. 2015, 182, 403–411. [CrossRef] [PubMed]
37. Margeta, M.; Connolly, A.M.; Winder, T.L.; Pestronk, A.; Moore, S.A. Cardiac pathology exceeds skeletal
muscle pathology in two cases of limb-girdle muscular dystrophy type 2i. Muscle Nerve 2009, 40, 883–889.
[CrossRef]
38. Tan, N.; Chung, M.K.; Smith, J.D.; Hsu, J.; Serre, D.; Newton, D.W.; Castel, L.; Soltesz, E.; Pettersson, G.;
Gillinov, A.M.; et al. Weighted gene coexpression network analysis of human left atrial tissue identifies gene
modules associated with atrial fibrillation. Circ. Cardiovasc. Genet. 2013, 6, 362–371. [CrossRef] [PubMed]
39. Wang, X.; Tucker, N.R.; Rizki, G.; Mills, R.; Krijger, P.H.; de Wit, E.; Subramanian, V.; Bartell, E.; Nguyen, X.X.;
Ye, J.; et al. Discovery and validation of sub-threshold genome-wide association study loci using epigenomic
signatures. eLife 2016, 5. [CrossRef] [PubMed]
40. Gingold-Belfer, R.; Bergman, M.; Alcalay, Y.; Schlesinger, H.; Aravot, D.; Berman, M.; Salman, H.; Brand, T.;
Kessler-Icekson, G. Popeye domain-containing 1 is down-regulated in failing human hearts. Int. J. Mol. Med.
2011, 27, 25–31. [PubMed]
41. Poon, K.L.; Brand, T. The zebrafish model system in cardiovascular research: A tiny fish with mighty
prospects. Glob. Cardiol. Sci. Pract. 2013, 2013, 9–28. [CrossRef] [PubMed]
42. Osler, M.E.; Chang, M.S.; Bader, D.M. Bves modulates epithelial integrity through an interaction at the tight
junction. J. Cell Sci. 2005, 118, 4667–4678. [CrossRef] [PubMed]
43. Zihni, C.; Balda, M.S.; Matter, K. Signalling at tight junctions during epithelial differentiation and microbial
pathogenesis. J. Cell Sci. 2014, 127, 3401–3413. [CrossRef] [PubMed]
44. Rhett, J.M.; Jourdan, J.; Gourdie, R.G. Connexin 43 connexon to gap junction transition is regulated by zonula
occludens-1. Mol. Biol. Cell 2011, 22, 1516–1528. [CrossRef] [PubMed]
45. Soni, S.; Raaijmakers, A.J.A.; Raaijmakers, L.M.; Damen, J.M.A.; van Stuijvenberg, L.; Vos, M.A.; Heck, A.J.R.;
van Veen, T.A.B.; Scholten, A. A proteomics approach to identify new putative cardiac intercalated disk
proteins. PLoS ONE 2016, 11, e0152231. [CrossRef] [PubMed]
46. Lindskog, C.; Linne, J.; Fagerberg, L.; Hallstrom, B.M.; Sundberg, C.J.; Lindholm, M.; Huss, M.; Kampf, C.;
Choi, H.; Liem, D.A.; et al. The human cardiac and skeletal muscle proteomes defined by transcriptomics
and antibody-based profiling. BMC Genom. 2015, 16, 475. [CrossRef] [PubMed]
47. Somekawa, S.; Fukuhara, S.; Nakaoka, Y.; Fujita, H.; Saito, Y.; Mochizuki, N. Enhanced functional gap
junction neoformation by protein kinase a-dependent and epac-dependent signals downstream of camp in
cardiac myocytes. Circ. Res. 2005, 97, 655–662. [CrossRef] [PubMed]
48. Lee, T.M.; Lin, S.Z.; Chang, N.C. Both pka and epac pathways mediate N-acetylcysteine-induced connexin43
preservation in rats with myocardial infarction. PLoS ONE 2013, 8, e71878. [CrossRef] [PubMed]
49. Hager, H.A.; Roberts, R.J.; Cross, E.E.; Proux-Gillardeaux, V.; Bader, D.M. Identification of a novel bves
function: Regulation of vesicular transport. EMBO J. 2010, 29, 532–545. [CrossRef] [PubMed]
J. Cardiovasc. Dev. Dis. 2016, 3, 22 17 of 19
50. Benesh, E.C.; Miller, P.M.; Pfaltzgraff, E.R.; Grega-Larson, N.E.; Hager, H.A.; Sung, B.H.; Qu, X.; Baldwin, H.S.;
Weaver, A.M.; Bader, D.M. Bves and ndrg4 regulate directional epicardial cell migration through autocrine
extracellular matrix deposition. Mol. Biol. Cell 2013, 24, 3496–3510. [CrossRef] [PubMed]
51. Smith, T.K.; Hager, H.A.; Francis, R.; Kilkenny, D.M.; Lo, C.W.; Bader, D.M. Bves directly interacts with geft,
and controls cell shape and movement through regulation of rac1/cdc42 activity. Proc. Natl. Acad. Sci. USA
2008, 105, 8298–8303. [CrossRef] [PubMed]
52. Sudhof, T.C. Neurotransmitter release: The last millisecond in the life of a synaptic vesicle. Neuron 2013, 80,
675–690. [CrossRef] [PubMed]
53. Schwenk, R.W.; Angin, Y.; Steinbusch, L.K.; Dirkx, E.; Hoebers, N.; Coumans, W.A.; Bonen, A.; Broers, J.L.;
van Eys, G.J.; Glatz, J.F.; et al. Overexpression of vesicle-associated membrane protein (vamp) 3, but not
vamp2, protects glucose transporter (glut) 4 protein translocation in an in vitro model of cardiac insulin
resistance. J. Biol. Chem. 2012, 287, 37530–37539. [CrossRef] [PubMed]
54. Braiman, L.; Alt, A.; Kuroki, T.; Ohba, M.; Bak, A.; Tennenbaum, T.; Sampson, S.R. Activation of protein
kinase c zeta induces serine phosphorylation of vamp2 in the glut4 compartment and increases glucose
transport in skeletal muscle. Mol. Cell. Biol. 2001, 21, 7852–7861. [CrossRef] [PubMed]
55. Tajika, Y.; Sato, M.; Murakami, T.; Takata, K.; Yorifuji, H. Vamp2 is expressed in muscle satellite cells and
up-regulated during muscle regeneration. Cell Tissue Res. 2007, 328, 573–581. [CrossRef] [PubMed]
56. Luftman, K.; Hasan, N.; Day, P.; Hardee, D.; Hu, C. Silencing of vamp3 inhibits cell migration and
integrin-mediated adhesion. Biochem. Biophys. Res. Commun. 2009, 380, 65–70. [CrossRef] [PubMed]
57. Hasan, N.; Hu, C. Vesicle-associated membrane protein 2 mediates trafficking of alpha5beta1 integrin to the
plasma membrane. Exp. Cell Res. 2010, 316, 12–23. [CrossRef] [PubMed]
58. Sztal, T.E.; Sonntag, C.; Hall, T.E.; Currie, P.D. Epistatic dissection of laminin-receptor interactions in
dystrophic zebrafish muscle. Hum. Mol. Genet. 2012, 21, 4718–4731. [CrossRef] [PubMed]
59. Goody, M.F.; Sher, R.B.; Henry, C.A. Hanging on for the ride: Adhesion to the extracellular matrix mediates
cellular responses in skeletal muscle morphogenesis and disease. Dev. Biol. 2015, 401, 75–91. [CrossRef]
[PubMed]
60. Hall, T.E.; Bryson-Richardson, R.J.; Berger, S.; Jacoby, A.S.; Cole, N.J.; Hollway, G.E.; Berger, J.; Currie, P.D.
The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient
congenital muscular dystrophy. Proc. Natl. Acad. Sci. USA 2007, 104, 7092–7097. [CrossRef] [PubMed]
61. Riggs, K.A.; Hasan, N.; Humphrey, D.; Raleigh, C.; Nevitt, C.; Corbin, D.; Hu, C. Regulation of integrin
endocytic recycling and chemotactic cell migration by syntaxin 6 and vamp3 interaction. J. Cell Sci. 2012, 125,
3827–3839. [CrossRef] [PubMed]
62. Hager, H.A.; Bader, D.M. Bves: Ten years after. Histol. Histopathol. 2009, 24, 777–787. [PubMed]
63. Bryan, B.A.; Mitchell, D.C.; Zhao, L.; Ma, W.; Stafford, L.J.; Teng, B.B.; Liu, M. Modulation of muscle
regeneration, myogenesis, and adipogenesis by the rho family guanine nucleotide exchange factor geft.
Mol. Cell. Biol. 2005, 25, 11089–11101. [CrossRef] [PubMed]
64. Bryan, B.A.; Cai, Y.; Liu, M. The rho-family guanine nucleotide exchange factor geft enhances retinoic acid-
and camp-induced neurite outgrowth. J. Neurosci. Res. 2006, 83, 1151–1159. [CrossRef] [PubMed]
65. Honore, E. The neuronal background k2p channels: Focus on trek1. Nat. Rev. Neurosci. 2007, 8, 251–261.
[CrossRef] [PubMed]
66. Hund, T.J.; Snyder, J.S.; Wu, X.; Glynn, P.; Koval, O.M.; Onal, B.; Leymaster, N.D.; Unudurthi, S.D.; Curran, J.;
Camardo, C.; et al. Betaiv-spectrin regulates trek-1 membrane targeting in the heart. Cardiovasc. Res. 2014, 102,
166–175. [CrossRef] [PubMed]
67. Cunha, S.R.; Mohler, P.J. Ankyrin protein networks in membrane formation and stabilization. J. Cell.
Mol. Med. 2009, 13, 4364–4376. [CrossRef] [PubMed]
68. Hund, T.J.; Unudurthi, S.D.; Wu, X.; Qian, L.; Amari, F.; Onal, B.; Li, N.; Makara, M.; Smith, S.; Snyder, J.; et al.
The two-pore K+ channel TREK-1 regulates sinoatrial node membrane excitability. J. Am. Heart Assoc.
2016, 20, e002865.
69. Gazzerro, E.; Sotgia, F.; Bruno, C.; Lisanti, M.P.; Minetti, C. Caveolinopathies: From the biology of caveolin-3
to human diseases. Eur. J. Hum. Genet. 2010, 18, 137–145. [CrossRef] [PubMed]
70. Lo, H.P.; Nixon, S.J.; Hall, T.E.; Cowling, B.S.; Ferguson, C.; Morgan, G.P.; Schieber, N.L.;
Fernandez-Rojo, M.A.; Bastiani, M.; Floetenmeyer, M.; et al. The caveolin-cavin system plays a conserved and
critical role in mechanoprotection of skeletal muscle. J. Cell Biol. 2015, 210, 833–849. [CrossRef] [PubMed]
J. Cardiovasc. Dev. Dis. 2016, 3, 22 18 of 19
71. Parton, R.G.; Way, M.; Zorzi, N.; Stang, E. Caveolin-3 associates with developing t-tubules during muscle
differentiation. J. Cell Biol. 1997, 136, 137–154. [CrossRef] [PubMed]
72. Galbiati, F.; Engelman, J.A.; Volonte, D.; Zhang, X.L.; Minetti, C.; Li, M.; Hou, H., Jr.; Kneitz, B.; Edelmann, W.;
Lisanti, M.P. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of
the dystrophin-glycoprotein complex, and t-tubule abnormalities. J. Biol. Chem. 2001, 276, 21425–21433.
[CrossRef] [PubMed]
73. Woodman, S.E.; Park, D.S.; Cohen, A.W.; Cheung, M.W.; Chandra, M.; Shirani, J.; Tang, B.; Jelicks, L.A.;
Kitsis, R.N.; Christ, G.J.; et al. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show
hyperactivation of the p42/44 mapk cascade. J. Biol. Chem. 2002, 277, 38988–38997. [CrossRef] [PubMed]
74. Roostalu, U.; Strahle, U. In vivo imaging of molecular interactions at damaged sarcolemma. Dev. Cell 2012, 22,
515–529. [CrossRef] [PubMed]
75. Magri, F.; del Bo, R.; D’Angelo, M.G.; Sciacco, M.; Gandossini, S.; Govoni, A.; Napoli, L.; Ciscato, P.;
Fortunato, F.; Brighina, E.; et al. Frequency and characterisation of anoctamin 5 mutations in a cohort
of italian limb-girdle muscular dystrophy patients. Neuromuscul. Disord. 2012, 22, 934–943. [CrossRef]
[PubMed]
76. Kubisch, C.; Schoser, B.G.; von During, M.; Betz, R.C.; Goebel, H.H.; Zahn, S.; Ehrbrecht, A.; Aasly, J.;
Schroers, A.; Popovic, N.; et al. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle
disease. Ann. Neurol. 2003, 53, 512–520. [CrossRef] [PubMed]
77. Bansal, D.; Miyake, K.; Vogel, S.S.; Groh, S.; Chen, C.C.; Williamson, R.; McNeil, P.L.; Campbell, K.P. Defective
membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423, 168–172. [CrossRef] [PubMed]
78. Weiler, T.; Bashir, R.; Anderson, L.V.; Davison, K.; Moss, J.A.; Britton, S.; Nylen, E.; Keers, S.; Vafiadaki, E.;
Greenberg, C.R.; et al. Identical mutation in patients with limb girdle muscular dystrophy type 2b or miyoshi
myopathy suggests a role for modifier gene(s). Hum. Mol. Genet. 1999, 8, 871–877. [CrossRef] [PubMed]
79. Han, R.; Bansal, D.; Miyake, K.; Muniz, V.P.; Weiss, R.M.; McNeil, P.L.; Campbell, K.P. Dysferlin-mediated
membrane repair protects the heart from stress-induced left ventricular injury. J. Clin. Investig. 2007, 117,
1805–1813. [CrossRef] [PubMed]
80. Gao, Q.Q.; McNally, E.M. The dystrophin complex: Structure, function, and implications for therapy.
Compr. Physiol. 2015, 5, 1223–1239. [PubMed]
81. Falzarano, M.S.; Scotton, C.; Passarelli, C.; Ferlini, A. Duchenne muscular dystrophy: From diagnosis to
therapy. Molecules 2015, 20, 18168–18184. [CrossRef] [PubMed]
82. Strehle, E.M.; Straub, V. Recent advances in the management of duchenne muscular dystrophy.
Arch. Dis. Child. 2015, 100, 1173–1177. [CrossRef] [PubMed]
83. Parang, B.; Kaz, A.; Barett, C.; Short, S.; Ning, W.; Keating, C.; Mittal, M.; Naik, R.; Washington, M.;
Revetta, F.; et al. Bves regulates c-myc stability via pp2a and suppresses 1 colitis-induced tumorigenesis.
Gut 2016. [CrossRef]
84. Miner, J.H.; Wold, B.J. C-myc inhibition of myod and myogenin-initiated myogenic differentiation.
Mol. Cell. Biol. 1991, 11, 2842–2851. [CrossRef] [PubMed]
85. Jackson, T.; Allard, M.F.; Sreenan, C.M.; Doss, L.K.; Bishop, S.P.; Swain, J.L. The c-myc proto-oncogene
regulates cardiac development in transgenic mice. Mol. Cell. Biol. 1990, 10, 3709–3716. [CrossRef] [PubMed]
86. Komuro, I.; Kurabayashi, M.; Takaku, F.; Yazaki, Y. Expression of cellular oncogenes in the myocardium
during the developmental stages and pressure-overloaded hypertrophy of the heart. Circ. Res. 1988, 62,
1075–1079. [CrossRef] [PubMed]
87. Zhong, W.; Mao, S.; Tobis, S.; Angelis, E.; Jordan, M.C.; Roos, K.P.; Fishbein, M.C.; de Alboran, I.M.;
MacLellan, W.R. Hypertrophic growth in cardiac myocytes is mediated by myc through a cyclin
d2-dependent pathway. EMBO J. 2006, 25, 3869–3879. [CrossRef] [PubMed]
88. Lee, H.G.; Chen, Q.; Wolfram, J.A.; Richardson, S.L.; Liner, A.; Siedlak, S.L.; Zhu, X.; Ziats, N.P.;
Fujioka, H.; Felsher, D.W.; et al. Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic
cardiomyopathy and heart failure. PLoS ONE 2009, 4, e7172. [CrossRef] [PubMed]
89. McConnachie, G.; Langeberg, L.K.; Scott, J.D. Akap signaling complexes: Getting to the heart of the matter.
Trends Mol. Med. 2006, 12, 317–323. [CrossRef] [PubMed]
90. Dodge-Kafka, K.L.; Soughayer, J.; Pare, G.C.; Carlisle Michel, J.J.; Langeberg, L.K.; Kapiloff, M.S.; Scott, J.D.
The protein kinase a anchoring protein makap coordinates two integrated camp effector pathways. Nature
2005, 437, 574–578. [CrossRef] [PubMed]
J. Cardiovasc. Dev. Dis. 2016, 3, 22 19 of 19
91. Parnell, E.; Smith, B.O.; Yarwood, S.J. The camp sensors, epac1 and epac2, display distinct subcellular
distributions despite sharing a common nuclear pore localisation signal. Cell Signal. 2015, 27, 989–996.
[CrossRef] [PubMed]
92. Kritzer, M.D.; Li, J.; Dodge-Kafka, K.; Kapiloff, M.S. Akaps: The architectural underpinnings of local camp
signaling. J. Mol. Cell. Cardiol. 2012, 52, 351–358. [CrossRef] [PubMed]
93. Kritzer, M.D.; Li, J.; Passariello, C.L.; Gayanilo, M.; Thakur, H.; Dayan, J.; Dodge-Kafka, K.; Kapiloff, M.S.
The scaffold protein muscle a-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic
signaling required for the development of heart failure. Circ. Heart Fail. 2014, 7, 663–672. [CrossRef]
[PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
